Is There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation?

The fair value estimate for MoonLake Immunotherapeutics matches the analyst price target at US$73.92. By utilizing the Discounted Cash Flow model, the intrinsic value of the stock is calculated based on future cash flows, considering growth rates and discounting to present value.